Profile banner
Aashish Rajput

Aashish Rajput

Medical Lead — Uro‑Oncology & Gastroenterology

Mumbai, Maharashtra, India
rocketreach
Joined March 2026

Network

3.7K connections
🤝
Ferring Commercial Leaders
⚕️
Ferring Medical Affairs
🌐
Ferring Global Operations
📈
Alkem Marketing Sales
🧪
Alkem Medical Clinical
🎓
Academic Medical
🌱
Alkem HR L&D

Summary

Specialty medical affairs leader focusing on uro-oncology and gastroenterology with a recent appointment at Ferring Pharmaceuticals, responsible for collaborating with cross-functional teams to support product strategy and patient outcomes within the specialty medicine pipeline. theorg
Experienced medical lead in diabetes and metabolic disorders who has contributed to multicentric clinical research (the MESIDA trial) while affiliated with Alkem Laboratories, demonstrating involvement in clinical development and publication. springer+1
Clinically trained physician with postgraduate training in pharmacology (MD) and hands-on experience as a resident doctor, tutor, research physician, and clinical investigator during early career stages. theorg+1
Bridges medical and commercial domains through formal management education (PGDMM at NMIMS) and pharmaceutical medical affairs roles, reflecting combined expertise in clinical science and product/brand strategy. rocketreach+1

Work

Education

Writing

A randomized, double-blind, active-controlled trial assessing the efficacy and safety of a fixed-dose combination (FDC) of Metformin hydrochloride 1000 mg ER, Sitagliptin phosphate 100 mg, and Dapagliflozin propanediol 10 mg in Indian adults with type 2 diabetes: The MESIDA trial

February 1, 2024

Multicentric, randomized, double-blind, active-controlled Phase 3 study comparing triple-drug FDC (metformin, sitagliptin, dapagliflozin) versus dual-drug FDC (metformin, sitagliptin) in Indian adults with type 2 diabetes; reports superior HbA1c lowering with the triple FDC and favorable safety profiles.

Favicon imagelink.springer.com